Abingdon Health (LON: ABDX) shares are down 13% today. This is a little unkind as a reaction to the ABDX results. For they’re actually pretty good. Or at least much better.
As we’ve said before there’s now a real product at Abingdon Health: “Abingdon Health (LON: ABDX) shares are up 25% this morning. ABDX shares have risen on the launch of a saliva based pregnancy test in Tesco. This is, as long term holders of Abingdon will be glad to note, an actual product which people voluntarily buy. Which is one of those innovations for the company. OK, that’s just us being cynics. But Abingdon Health has not done well by shareholders these past few years. The reason being that it came to market in the middle of all that fuss about covid, lockdown and the absence of testing kits. So, testing kits were designed and rolled out - but they came rather late. The big, juicy, government contracts had already gone by the time it was ready. There were also problems with the actual efficacy of the tests themselves. There were several companies in this sort of position on the London market. We even saw a near coordinated rise in them as they all declared that had achieved CE Marks - without quite pointing out that a CE mark is not like an FDA approval, it’s just self-certification and the payment of the relevant fee.”
The results make the same point: “With our transition away from COVID-19 activities” and “Salistick™, the first ever saliva pregnancy test, launched in 400 Superdrug stores and online, via Amazon and on the Abingdon Simply Test website in June 2023, followed by its roll-out in 298 Tesco stores and Tesco online in August 2023.” It’s a wildly different business to that of two and three years ago.
Abingdon Health share price from Google Finance
The financial results are better too: “Revenue of £4.0m (2022: £2.8m), with H2 2023 revenue of £2.9m being over 2.5x that of H1 2023 (H1 2023: £1.1m) reflecting increasing commercial momentum over the year. YoY revenue growth of 126% in FY23 when excluding COVID-19-related sales from both years.” And so on. Perhaps the most important point is that they don’t think a capital raise will be necessary.
So, why do the shares fall on this news? Simply because most of this was known already. Therefore the rise in the ABDX share price ahead of the announcement was that hope that they’d be even better. They weren’t so that hope value now recedes. As so often in stock markets buy the rumour and sell the fact.